IDDI
eClinical and Biostatistical Services

The IDDI group, with a staff of around 50 people and a turnover of € 6 M in 2010 (90% from exports), combines expert methodology and innovative technology to optimise the design and conduct of clinical trials from phase I to IV.

Established in 1991 and based in Louvain-la-Neuve since 2006, IDDI (International Drug Development Institute) doubled its turnover between 2006 and 2010 and expects to do so again between 2010 and 2014. The dynamic development of the group is based on its niche positioning in the fields of biostatistics, data management and central randomisation (automation of controlled allocation of treatments in randomised clinical trials). IDDI also provides biostatistical support for the design of trial protocols and acts as an expert for interactions with regulatory agencies (EMA, FDA).

Methodological support is the core of IDDI's expertise. Comparable to high-level consultancy, it integrates biostatistical know-how in many therapeutic areas (with emphasis on oncology, ophthalmology and cardiology) and enables the optimal design of clinical trial protocols in order to obtain results more swiftly. In parallel, IDDI provides made-to-measure secure Internet systems: ID-net™ (on-line randomisation with an emergency unblinding feature, drug supply management and real-time reports); Marvin by XClinical, an electronic patient case report form (Electronic CRF); TrialControl™, a portal for sharing documents and key data; and ID-code™, a system for coding medical terms according to the MedDRA® and WHO-Drug Dictionary.

In 20 years of activity, IDDI has conducted around 500 clinical trials and contributed to 14 approvals to market new drugs in Europe and the USA. The group is currently working on 150 projects for 60 clients (40% of which are biotechnology companies, 35% pharmaceutical groups and 20% academic groups). The most recently assigned projects deal with disorders of the digestive system of children undergoing chemotherapy, assessment of the tolerance and efficiency of a molecule for the treatment of age-related macular degeneration, the progression to phase III of an immunotherapy agent against lung cancer and a clinical trial programme assessing the non-inferiority of a biosimilar in the treatment of breast cancer.

© IDDI

The main IDDI building

© IDDI

Biostatistics is the core of IDDI's expertise.

Moreover, IDDI is involved in 2 research projects which could further its growth. The SMART project, developed with the financial support of the Walloon Region, aims to design statistical monitoring with a view to detecting heterogeneity of data across investigational centres and to create a quality label for clinical trial data. The second project, under the EurotransBio initiative, targets a methodology for the validation of biomarkers that could predict the efficacy of medicines assessed for the treatment of Alzheimer's disease.

The same development perspective underlies IDDI's strategic choices, starting with that of the particularly promising North American market (40% of total turnover in 2009), and Asian emerging countries. IDDI's profile is also enhanced by its webinars (3 on-line seminars organised in 2010) and by visits abroad. Last November the group ran training sessions on central randomisation and electronic case report forms for some of the big players of the Chinese pharmaceutical and CRO industry.

IDDI
Adding Value to Clinical Data

IDDI
Avenue Provinciale, 30 - B-1340 Louvain-la-Neuve
Tel.: +32 (0)10 61 44 44 - Fax: +32 (0)10 61 88 88
E-mail: damien.tremolet@iddi.com - http://www.iddi.com